Invesco Mortgage Capital (IVR) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
20 Mar, 2026Executive summary
Annual meeting scheduled for May 5, 2026, at 1:00 P.M. ET in Atlanta, Georgia.
Proxy materials and 2025 Annual Report are available online for review and voting.
Shareholders are encouraged to vote electronically or request paper materials by April 21, 2026.
Voting matters and shareholder proposals
Election of six directors: Robert L. Fleshman, Katharine W. Kelley, Stephanie J. Larosiliere, Don H. Liu, W. Wesley McMullan, and Robert B. Waldner.
Advisory vote to approve executive compensation as disclosed in the proxy statement.
Ratification of PricewaterhouseCoopers LLP as independent registered public accounting firm for 2026.
Board recommends voting FOR all nominees and FOR Proposals 2 and 3.
Board of directors and corporate governance
Board slate includes six nominees for election at the annual meeting.
Latest events from Invesco Mortgage Capital
- Board refreshment, strong returns, and robust governance highlight this year's proxy agenda.IVR
Proxy filing20 Mar 2026 - Book value per share rose 3.7% to $8.72, with an 8.0% economic return and higher dividend.IVR
Q4 20252 Feb 2026 - Book value per share fell 8% in Q2, but distributable earnings and dividend remained stable.IVR
Q2 20241 Feb 2026 - Q3 2024 saw a return to profitability, higher book value, and a 5.4% economic return.IVR
Q3 202416 Jan 2026 - Book value dropped 4.8% in Q4, with net loss and improved capital structure amid volatility.IVR
Q4 202423 Dec 2025 - Shelf registration allows up to $650M in securities for REIT investment and capital needs.IVR
Registration Filing16 Dec 2025 - Board seeks approval for director elections, executive pay, and auditor ratification amid strong governance.IVR
Proxy Filing1 Dec 2025 - Director elections, executive pay, and auditor ratification up for vote at May 2025 meeting.IVR
Proxy Filing1 Dec 2025 - Earnings rebounded in Q1 2025, but book value fell as volatility and risks persisted.IVR
Q1 202525 Nov 2025